Development of Neuropathic Arthropathy With Entrectinib: Case Report

Nicholas P Giustini; Hanna Oh; Keith D Eaton

doi:10.1016/j.jtocrr.2022.100419

Development of Neuropathic Arthropathy With Entrectinib: Case Report

JTO Clin Res Rep. 2022 Sep 30;3(11):100419. doi: 10.1016/j.jtocrr.2022.100419. eCollection 2022 Nov.

Authors

Nicholas P Giustini¹, Hanna Oh², Keith D Eaton^{3

4}

Affiliations

¹ Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington.
² Department of Rehabilitation Medicine, University of Washington, Seattle, Washington.
³ Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.
⁴ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.

Abstract

TRK inhibition can lead to on-target neurologic adverse events. Two cases illustrate the development of neuropathic arthropathy as a side effect of entrectinib. After starting entrectinib, both patients developed foot pain, swelling, and sensory changes with magnetic resonance imaging revealing marrow edema. Providers should have a low threshold to investigate foot pain or gait abnormalities thoroughly with magnetic resonance imaging and referral to specialists to aid in the diagnosis of neuropathic arthropathy, with consideration to transition to an alternative agent.

Keywords: Case report; Entrectinib; NTRK; Neuropathic Charcot arthropathy.

Publication types

Case Reports